This brand name is authorized in South Africa
The drug ORIMETEN contains one active pharmaceutical ingredient (API):
|
1
Aminogluthetimide
UNII 0O54ZQ14I9 - AMINOGLUTETHIMIDE
|
|
Aminoglutethimide has two mechanisms of action: it blocks aromatase in the generation of estrogens from androstenedione and testosterone; it blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme P450scc and consequently decreases synthesis of all hormonally active steroids. At low doses, aminogluthethimide is only an effective inhibitor of aromatase, but at higher doses, it effectively blocks P450scc as well. It is used in the treatment of Cushing’s syndrome. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02BG01 | Aminogluthetimide | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BG Aromatase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): P/21.12/274 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
